ISGF3 and STAT2/IRF9 Control Basal and IFN-Induced Transcription through Genome-Wide Binding of Phosphorylated and Unphosphorylated Complexes to Common ISRE-Containing ISGs

Int J Mol Sci. 2023 Dec 18;24(24):17635. doi: 10.3390/ijms242417635.

Abstract

In addition to the canonical ISGF3 and non-canonical STAT2/IRF9 complexes, evidence is emerging of the role of their unphosphorylated counterparts in IFN-dependent and -independent ISG transcription. To better understand the relation between ISGF3 and U-ISGF3 and STAT2/IRF9 and U-STAT2/IRF9 in IFN-I-stimulated transcriptional responses, we performed RNA-Seq and ChIP-Seq, in combination with phosphorylation inhibition and antiviral experiments. First, we identified a group of ISRE-containing ISGs that were commonly regulated in IFNα-treated WT and STAT1-KO cells. Thus, in 2fTGH and Huh7.5 WT cells, early and long-term IFNα-inducible transcription and antiviral activity relied on the DNA recruitment of the ISGF3 components STAT1, STAT2 and IRF9 in a phosphorylation- and time-dependent manner. Likewise, in ST2-U3C and Huh-STAT1KO cells lacking STAT1, delayed IFN responses correlated with DNA binding of phosphorylated STAT2/IRF9 but not U-STAT2/IRF9. In addition, comparative experiments in U3C (STAT1-KO) cells overexpressing all the ISGF3 components (ST1-ST2-IRF9-U3C) revealed U-ISGF3 (and possibly U-STAT2/IRF9) chromatin interactions to correlate with phosphorylation-independent ISG transcription and antiviral activity. Together, our data point to the dominant role of the canonical ISGF3 and non-canonical STAT2/IRF9, without a shift to U-ISGF3 or U-STAT2/IRF9, in the regulation of early and prolonged ISG expression and viral protection. At the same time, they suggest the threshold-dependent role of U-ISFG3, and potentially U-STAT2/IRF9, in the regulation of constitutive and possibly long-term IFNα-dependent responses.

Keywords: IFN-dependent and -independent transcription; ISGF3; JAK/STAT signaling; STAT2/IRF9; U-ISGF3; U-STAT2/IRF9; integrative omics approach; interferon type-I.

MeSH terms

  • Antiviral Agents / pharmacology
  • DNA / pharmacology
  • Humans
  • Immunoglobulins / metabolism
  • Interferon Type I* / metabolism
  • Interferon-Stimulated Gene Factor 3* / metabolism
  • Interleukin-1 Receptor-Like 1 Protein* / metabolism
  • STAT1 Transcription Factor / metabolism
  • STAT2 Transcription Factor* / metabolism
  • Signal Transduction

Substances

  • Antiviral Agents
  • DNA
  • Immunoglobulins
  • Interferon Type I
  • Interleukin-1 Receptor-Like 1 Protein
  • STAT1 Transcription Factor
  • Interferon-Stimulated Gene Factor 3
  • STAT2 Transcription Factor
  • IRF9 protein, human

Grants and funding

This research was funded by the National Research Centre Poland, grant number UMO-2016/21/N/NZ2/01720 (HN), UMO-2016/23/B/NZ2/00623 (HB) and the National Centre for Research and Development grant: “Passport to the future—Interdisciplinary doctoral studies at the Faculty of Biology UAM” POWR.03.02.00-00-I006/17 (HN); Project-based Personnel Exchange Program (PPP) between the MOST (Ministry of Science and Technology), Taiwan and the PAS (Polish Academy of Science), Poland (Project #104-2911-I-002-522) (HB).